COVID-19 trials registries data warehouse

 Return to trial list

Trial - NCT04770740


Column Value
Trial registration number NCT04770740
Full text link
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

First author
Last imported at : June 14, 2022, 5:30 p.m.
Source : ClinicalTrials.gov

A Dofferhoff

Contact
Last imported at : June 14, 2022, 5:30 p.m.
Source : ClinicalTrials.gov

Not reported

Registration date
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

2021-02-25

Recruitment status
Last imported at : June 14, 2022, 5:30 p.m.
Source : ClinicalTrials.gov

Completed

Study design
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

RCT

Allocation
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

Randomized

Design
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

Parallel

Masking
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

Blind label

Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov

single-center

Study aim
Last imported at : June 14, 2022, 5:30 p.m.
Source : ClinicalTrials.gov

Treatment

Inclusion criteria
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

inclusion criteria: - covid-19 patients who are admitted to the cwz with covid-19, with a laboratory confirmed sars-cov-2 infection within the previous 96 hours - respiratory failure requiring supplemental oxygen, defined as requiring supplemental oxygen to sustain an arterial po2 ≥70mmhg (measured by arterial blood gas) or an oxygen saturation of ≥94% (measured using a pulse oximeter) - at least 18 years old - able to safely swallow the study medication or possibility of safely administering this through a nasogastric tube - use of prophylactic heparin or lwmh according to hospital protocols, or use of therapeutic dosages if there is a medical indication for this - informed consent signed by patient

Exclusion criteria
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

- use of oral anticoagulation drugs; patients may be included when they have been switched to lmwh - patients on vitamin k antagonists with a supra-therapeutic anticoagulation at admission who require vitamin k supplementation to correct this, or were administered vitamin k for this reason within the preceding 5 days - patients already using vitamin k supplements at admission - participation in another intervention study - direct admission to an intensive care unit (icu) for invasive ventilation at presentation - confirmed active pulmonary embolism or deep venous thrombosis prior to inclusion - known allergy to any of the components of the study medication or placebo - patients who are hemodialysis dependent at admission - pregnancy at the time of inclusion - diagnosed malignancy at the time of inclusion

Number of arms
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

2

Funding
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

Canisius-Wilhelmina Hospital

Inclusion age min
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

18

Inclusion age max
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

100

Countries
Last imported at : March 5, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

Netherlands

Type of patients
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

Severe disease at enrollment

Severity scale
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

6: Severe disease at enrollment

Total sample size
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

40

primary outcome
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

Plasma desmosine levels;Plasma dp-ucMGP levels

Notes
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

None

Phase
Last imported at : June 14, 2022, 5:30 p.m.
Source : ClinicalTrials.gov

Not reported

Arms
Last imported at : Feb. 27, 2021, 12:31 a.m.
Source : ClinicalTrials.gov

[{"arm_notes": "", "treatment_id": 1373, "treatment_name": "Vitamin k2", "treatment_type": "Vitamins and dietary supplements", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]